Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM.
[1]. Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A? inhibition: results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9(1):e83094.
















